deferoxamine has been researched along with Acute Promyelocytic Leukemia in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we investigate whether these two agents influence the in vitro differentiation-inducing effect of arsenic trioxide (As2O3) on AML cells, an effective drug for the treatment of acute promyelocytic leukemia (APL) that is a unique subtype of AML with a specific fusion protein, PML-RARalpha." | 3.73 | Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. ( Chen, GQ; Huang, Y; Jiang, Y; Peng, ZG; Wu, YL; Yan, H; Yu, Y; Zhao, Q; Zhu, YS, 2005) |
| "0 microM, was included with each agent in dose-response studies, a synergistic enhancement of the antiproliferative effects was observed." | 1.27 | Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. ( Cohen, A; Estrov, Z; Freedman, MH; Gelfand, EW, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tamm, I | 1 |
| Yan, H | 1 |
| Peng, ZG | 1 |
| Wu, YL | 1 |
| Jiang, Y | 1 |
| Yu, Y | 1 |
| Huang, Y | 1 |
| Zhu, YS | 1 |
| Zhao, Q | 1 |
| Chen, GQ | 1 |
| Takeuchi, T | 1 |
| Morimoto, K | 1 |
| Kosaka, H | 1 |
| Shiga, T | 1 |
| Lundberg, JH | 1 |
| Chitambar, CR | 1 |
| Yung, BY | 1 |
| Yang, YH | 1 |
| Bor, AM | 1 |
| Estrov, Z | 1 |
| Cohen, A | 1 |
| Gelfand, EW | 1 |
| Freedman, MH | 1 |
6 other studies available for deferoxamine and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cell Hypox | 2005 |
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Differentiation; Cell Divisio | 2005 |
Spin trapping of superoxide released by opsonized asbestos from human promyelocytic leukemia cell line, HL60.
Topics: Asbestos; Asbestos, Crocidolite; Cell Differentiation; Cyclic N-Oxides; Deferoxamine; Dimethyl Sulfo | 1993 |
Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells.
Topics: Antineoplastic Agents; Cell Division; Deferoxamine; Drug Synergism; Edetic Acid; Gallium; Humans; Ir | 1990 |
Nucleolar protein B23 translocation after deferoxamine treatment in a human leukemia cell line.
Topics: Antibodies, Monoclonal; Cell Division; Cell Line; Cell Nucleolus; Cell Nucleus; Chlorides; Deferoxam | 1991 |
Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cytarabine; Daunorubicin; Deferoxamine; Dose-Response Re | 1988 |